Note: This is a daily stock update and the information stands true as of 27/08/26, 09:00 CET
Company Update:
FY26 results: organic net sales miss, recurring operating profit beat on lowered A&P.
Q4 sales down 2% organically, a clearly disappointing performance; FY26 net sales of EUR 9,404m, -3.9% organic, below consensus (-3.7%) and at the bottom of the guided range (-3% to -4%).
Profit from recurring operations of EUR 2,423m, -5.2% organic, above consensus (-5.9%) — but the beat comes from A&P at 15.0% of sales (low end of the c.16% guided, down 11% organically).
Free cash flow of EUR 1,197m (+6%), cash conversion at 91% (+17pts), well above target. Deleveraging continues (net debt/EBITDA at 3.7x).
FY27 guidance: organic net sales broadly stable (US and China still declining on inventory adjustments, continued growth in Rest of World); operating margin to be strongly defended through accelerated efficiencies and digital investment.
Mid-term FY27-29 guidance (partly revised down):
Net sales +3% to +6% p.a. now guided close to the lower end of the range, on US softness.
EUR 1bn efficiencies program accelerated to FY26-FY28 (from FY29), half delivered.
A miss on the top line and a beat on PRO, but the beat is mainly helped by lower A&P. The results are a bit disappointing. FCF conversion is improving and deleveraging continues, but FY27 guidance lacks precision and organic net sales growth is now guided at the lower end of the mid-term range. We expect a negative market reaction today.
Expert Opinion:
Q4 is a disappointment after two quarters of better sales performance. Is it a bump on the recovery road or does it invalidate the expected turnaround? In any case, issues in China and the US remain. While valuation is attractive (PE27 at 11.6x with a 6.5% div Yield) we would rather wait for an actual improvement of momentum in the US or China before committing more, capital on the name.
For daily updates, subscribe to our newsletter and for detailed information, reach out to us at sales@alphavalue.eu